A Japanese family with autosomal recessive cerebellar ataxia type 8 (SCAR8, MIM 610743) is described. We identified a novel SYNE1 frameshift deletion (c.6843del, p.Q2282Sfs*3). This family shared similar clinical manifestations characterized by adult-onset, relatively pure cerebellar ataxia with mild eye movement abnormality. Intelligence and bulbar and respiratory functions were unaffected. This study suggests the clinical utility of using panel-based exome sequencing for genetic diagnosis in hereditary ataxias in a cost-efficient manner.
Following recent progress in the development of highthroughput sequencing technologies, SCAR8-causing variants in SYNE1 have been reported worldwide. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Moreover, the clinical presentations of SCAR8 have expanded with variable combinations of cerebellar and extra-cerebellar neurological dysfunctions, including amyotrophic lateral sclerosis-like motor neuron features. 4, [9] [10] [11] However, little is known about how the loss of Nesprin-1 function causes the unique phenotypic variation of SCAR8.
Here, we report a Japanese SCAR8 family carrying a novel homozygous frameshift deletion in SYNE1 based on panel-based targeted exome sequencing. To the best of our knowledge, this is the fourth SCAR8 family reported in Japan. 4 We determined that they were carrying a novel homozygous frameshift deletion (c.6843delT, p.Q2282Sfs*3) in SYNE1 using panel-based targeted exome sequencing.
The proband (patient 1, IV-5), a 67-year-old Japanese woman, was born to consanguineous parents ( Figure 1a ). She had a family history of gait difficulty and dysarthria in her elder brother (IV-1), mother (III-12), and maternal grandmother (II-4). At age 22, she first noticed that her speech appeared to be slurred. She began falling while walking at age 35. A neurological examination at age 67 showed horizontal gaze-evoked nystagmus and saccadic intrusions during smooth pursuits. Her speech was slurred, but dysphagia was absent. She showed limb and truncal ataxia. There was no evidence of pyramidal sign, muscle atrophy, or sensory disturbances. Her total scale for assessment and rating of ataxia score was 26, and her inventory of non-ataxia signs score was 2. Her mini-mental state examination score was 24. Brain magnetic resonance imaging (MRI) at age 65 revealed atrophy in the cerebellar hemispheres and vermis. Cortical or brainstem atrophy was not evident (Figure 1b, c) .
Patient 2 (IV-1), a 74-year-old man, was the elder brother of patient 1. He suffered from gait difficulty at approximately age 30 and dysarthria at age 35. He became unable to walk at age 65. His neurological examination at age 74 showed saccadic eye movement, dysarthria, ataxic speech, limb, and truncal ataxia. There was no evidence of bulbar palsy, pyramidal sign, muscle atrophy, or sensory disturbances. His scale for assessment and rating of ataxia score was 35, inventory of non-ataxia signs score was 2, and mini-mental state examination score was 23. Brain MRI at age 73 showed atrophy in the cerebellar hemispheres and vermis (Figure 1d , e).
Patient 3 (III-12) was the mother of patients 1 and 2. She was also born to consanguineous parents and showed cerebellar ataxia. She first noticed gait difficulty and slurred speech at approximately age 30 and became unable to walk at age 40. She died at age 91.
Molecular diagnosis was performed on genomic DNA extracted from a blood sample after informed consent was obtained from patients 1 and 2 and their unaffected sister (IV-3). First, screening for common inherited dominant repeat expansion SCA genes, i.e., SCA1, SCA2, MJD/SCA3, SCA6, SCA7, SCA8, SCA12, SCA17, SCA31, and DRPLA was negative for patient 1. Next, to screen multiple SCA genes and other known ataxia-associated genes, we performed panel-based targeted exome sequencing for patient 1 using a TruSight One Sequencing Panel (Illumina, San Diego, CA, USA) and a MiSeq benchtop sequencer (Illumina). For data analysis, we used VariantStudio, version 2.2.1 (Illumina). This study was approved by the ethics committee at Shinshu University.
We found a homozygous novel deletion NM_033071.3 (SYNE1_v001):c.6843del in exon 46 of SYNE1 for patient 1. This deletion results in a frameshift at amino acid 2,285 out of 8,749, truncating the encoded protein (p.Q2282Sfs*3). No other mutations were detected in the coding regions of other ataxia-related genes (data not shown). This result was confirmed using Sanger sequencing, whereas the patient's affected brother (IV-1) was homozygous and her unaffected sister (IV-3) was heterozygous for this mutation (Figure 2a ). This mutation has not been described in human genome variation databases, including the 1000 Genomes Project (http://www.internationalgenome.org), Exome Aggregation Consortium (ExAC) (http://exac.broadinstitute.org) and Human Genetic Variation Database (HGVD) (http://www.genome. med.kyoto-u.ac.jp/SnpDB/), or in disease-causing mutation databases, such as the Human Gene Mutation Database (HGMD) Professional 2017.8 (http://www.hgmd.org/) and ClinVar (http:// www.ncbi.nlm.nih.gov/clinvar/).
The clinical manifestations of the family in this report are characterized by adult-onset, relatively pure cerebellar ataxia with mild eye movement abnormality. The overall clinical courses of our patients were very protracted. Brain images showed marked cerebellar atrophy, whereas the midbrain and pons were spared. These clinical features are similar to those of the aforementioned French-Canadian families. (Figure 2b ). Nesprin-1 has multiple alternative start and termination sites throughout SYNE1, allowing the generation of smaller alternating isoforms. 3 Razafsky et al. 15 noted that full-length Nesprin-1 (Nesprin-1 giant) and one of the isoforms of Nesprin-1 giant devoid of the KASH (KLNes1g) are specifically expressed in the central nervous system, whereas KLNes1g is expressed most abundantly expressed in the cerebellum. The detected mutation in our family could truncate multiple Nesprin-1 isoforms, including Nesprin-1 giant and KLNes1g (Figure 2b) . SYNE1 is also known as the disease-causing gene of autosomal dominant Emery-Dreifuss muscular dystrophy (EDMD4) 16 and autosomal recessive arthrogryposis multiplex congenital (AMC). 17 Most of the Emery-Dreifuss muscular dystrophy-causative mutations were heterozygous missense, suggesting that the pathogenesis of Emery-Dreifuss muscular dystrophy involves gain-offunction effects on Nesprin-1 (Figure 2b ). All arthrogryposis multiplex congenital-causative mutations would be expected to lack most of the KASH-containing isoforms, 17, 18 such as Nesprin-1α2, which is known as one of the predominantly muscle-specific isoforms. 19 In contrast, SCAR8-causative mutations are likely to affect Nesprin-1 giant and KLNes1g, and not affect the short KASH-containing isoforms. The nine SCAR8-causative mutations, which can truncate the Nesprin-1α2 isoform, were compound heterozygous with truncating variants outside the nesprin-1α2 region (Figure 2b ). These findings support the hypothesis that loss of the short KASH-containing alternative isoforms is sufficient to cause SYNE1-associated arthrogryposis multiplex congenital. 18 In SCAR8, there was no obvious correlation between the position of the truncation variants and clinical phenotype, which presented with and without motor neuron features (Figure 2b) . The pathological mechanisms underlying the SYNE1 mutations that cause phenotypic variations of SCAR8 remain to be elucidated.
In Japan, SCARs account for 1.8% of patients with ataxia. 20 However, the disease frequency of each subtype in SCARs is unclear because of Whole-exome sequencing is recognized as an effective tool for the diagnosis of rare diseases, whereas the cost of whole-exome sequencing is still unaffordable for most patients. This study suggests the clinical utility of using panel-based targeted exome sequencing for genetic diagnosis in hereditary ataxias. Studies involving an increased number of patients with SYNE1 mutations are needed to gain further insight into the molecular mechanisms of SYNE1-related diseases. SCAR8 with a novel SYNE1 variant T Yoshinaga et al
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